Rivaroxaban improves vascular response in LPS-induced acute inflammation in experimental models
Open Access
- 10 December 2020
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (12) , e0240669
Abstract
Rivaroxaban (RVX) was suggested to possess anti-inflammatory and vascular tone modulatory effects. The goal of this study was to investigate whether RVX impacts lipopolysaccharide (LPS)-induced acute vascular inflammatory response. Male rats were treated with 5 mg/kg RVX (oral gavage) followed by 10 mg/kg LPS i.p injection. Circulating levels of IL-6, MCP-1, VCAM-1, and ICAM-1 were measured in plasma 6 and 24 hours after LPS injection, while isolated aorta was used for gene expression analysis, immunohistochemistry, and vascular tone evaluation. RVX pre-treatment significantly reduced LPS mediated increase after 6h and 24h for IL-6 (4.4±2.2 and 2.8±1.7 fold), MCP-1 (1.4±1.5 and 1.3±1.4 fold) VCAM-1 (1.8±2.0 and 1.7±2.1 fold). A similar trend was observed in the aorta for iNOS (5.5±3.3 and 3.3±1.9 folds reduction, PvsLPS, Emax reduction = 35.4 and 31.19%, P0.05, respectively), resulting in 24.5% and 19.7% change in maximal constriction in LPS and LPS+RVX respectively. These data indicate that RVX pre-treatment attenuates LPS-induced acute vascular inflammation and contractile dysfunction.Keywords
Funding Information
- Ministry of Education, Science and Technology (2616)
This publication has 78 references indexed in Scilit:
- Proteinase-activated receptors (PARs) – focus on receptor-receptor-interactions and their physiological and pathophysiological impactCell Communication and Signaling, 2013
- RhoA/Rho-Kinase and Nitric Oxide in Vascular Reactivity in Rats with EndotoxaemiaPLOS ONE, 2013
- Direct inhibitors of thrombin and factor Xa attenuate clot-induced mitogenesis and inflammatory gene expression in human vascular smooth muscle cellsThrombosis and Haemostasis, 2011
- Evaluation of Plaque Stability of Advanced Atherosclerotic Lesions in Apo E-Deficient Mice after Treatment with the Oral Factor Xa Inhibitor RivaroxabanMediators of Inflammation, 2011
- Clinical Pharmacology of Direct and Indirect Factor Xa InhibitorsDrugs, 2010
- The Rho-A/Rho-kinase pathway is up-regulated but remains inhibited by cyclic guanosine monophosphate–dependent mechanisms during endotoxemia in small mesenteric arteries*Critical Care Medicine, 2009
- Animal models of sepsis and its complicationsKidney International, 2008
- The interactions between inflammation and coagulationBritish Journal of Haematology, 2005
- Pharmacokinetics of BAY 59-7939 – an oral, direct Factor Xa inhibitor – in rats and dogsXenobiotica, 2005
- In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitorJournal of Thrombosis and Haemostasis, 2005